Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study.

Author information

Affiliations

  • 1. Laboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Poland; Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Poland.
      Authors
    • Michlewska S 1
    (1 author)
  • 2. Department of Physics, Faculty of Science, J.E. Purkyně University in Ústí nad Labem, Pasteurova 15, 400 96 Ústí nad Labem, Czech Republic.
      Authors
    • Maly M 2
    (1 author)
  • 3. Department of Haemostatic Disorders, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka st. 6/8, 92-215 Lodz, Poland.
      Authors
    • Wójkowska D 3
    • Karolczak K 3
    • Watala C 3
    (3 authors)
  • 4. Institute of General and Ecological Chemistry, Lodz University of Technology, Żeromskiego 116, 90-924 Łódź, Poland.
      Authors
    • Skiba E 4
    (1 author)
  • 5. Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Poland.
      Authors
    • Hołota M 5
    • Kubczak M 5
    • Bryszewska M 5
    • Ionov M 5
    (4 authors)
    • Show all (7)

ORCIDs linked to this article

Show all (8)

International Journal of Pharmaceutics, 28 Feb 2023, 636:122784
https://doi.org/10.1016/j.ijpharm.2023.122784 PMID: 36858135 

Abstract 

The carbosilane metallodendrimer G1-[[NCPh(o-N)Ru(η6- p-cymene)Cl]Cl]4 (CRD13), based on an arene Ru(II) complex coordinated to imino-pyridine surface groups, has been conjugated with anti-cancer drugs. Ruthenium in the positively-charged dendrimer structure allows this nanoparticle to be considered as an anticancer drug carrier, made more efficient because ruthenium has anticancer properties. The ability of CRD13 to form complexes with Doxorubicin (DOX), 5-Fluorouracil (5-Fu), and Methotrexate (MTX) has been evaluated using zeta potential measurement, transmission electron microscopy (TEM) and computer simulation. The results show that it forms stable nanocomplexes with all those drugs, enhancing their effectiveness against MDA-MB-231 cancer cells. In vivo tests indicate that the CRD13/DOX system caused a decrease of tumor weight in mice with triple negative breast cancer. However, the tumors were most visibly reduced when naked dendrimers were injected.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.ijpharm.2023.122784

Citations & impact 

Impact metrics

2
Citations
Jump to Citations

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

European Cooperation in Science and Technology (1)

European Regional Development Fund

    European Social Fund (1)

    Grantová Agentura České Republiky (2)

    Horizon 2020 (1)

    Ministerstvo Školství, Mládeže a Tělovýchovy (1)

    Narodowe Centrum Nauki (1)